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and cytometry data showed moderate (0.40) to very strong 
(0.99) correlations. Thereby, we observed partially signifi-
cant differences in drug efficacy between microtissues and 
2D cultures dependent from the applied treatment and read-
out method. Altogether, microtissues developed resistance 
to cisplatin and vinorelbine; but remained more vulnerable 
to afatinib. These findings were confirmed with microscopy.
Conclusion In summary, we established an NSCLC 3D 
test system with multiple assays compatible for drug-test-
ing applications of substances with different mechanisms 
of action. In addition, our data support the usage of micro-
tissues as more accurate tools for drug-efficacy testing with 
the possibility of long-term cultivation and treatment.
Keywords Three-dimensional model · Lung cancer · Drug 
testing · Hanging-drop · In vivo mimicking
Introduction
The progress from drug discovery to its commercializa-
tion is complex, lengthy and expensive (Suggitt and Bibby 
2005). Currently, a drug candidate that enters Phase I tri-
als will successfully proceed further with a probability 
of just 8 %. This fact urges the need for quantitative and 
physiologically relevant cell culture in vitro systems bet-
ter resembling in vivo conditions. Therefore, new in vitro 
methods should be integrated in the drug-screening process 
(Pampaloni et al. 2007; Singh et al. 2015). A growing body 
of research is contributing to the use of three-dimensional 
(3D) tissue models to close the gap between two-dimen-
sional (2D) cell culture and animal models (Edmondson 
et al. 2014).
In vitro systems have the advantage to minimize ethi-
cal issues and to be more cost-effective compared to 
Abstract 
Background The focus of the outlined work is the estab-
lishment of a three-dimensional lung model for various 
drug-screening applications.
Methods The non-small cell lung cancer (NSCLC) cell line 
Colo699 was cultivated as monolayer (2D) on plates for 
5 days or as microtissues (3D) using a hanging-drop system 
for 5 and 10 days. Cells and microtissues were treated with 
afatinib (10–80 µM), cisplatin (100–800 µM) or vinorel-
bine (25–200 µM) for 24 or 48 hours (h). Cell prolifera-
tion and viability were analysed by intra-cellular adeno-
sine triphosphate (ATP) and lactate dehydrogenase release 
(LDH) assays, annexin V/propidium iodide (PI) staining, 
and cell cycle determination. Microtissue morphology and 
size, as well as cell death were evaluated via phase contrast 
microscopy.
Results Our results demonstrate the valid determination 
of viability and cell death using established assays in the 
3D system for drug testing. The comparison of ATP, LDH 
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in vivo models. Traditionally, in vitro drug testing and 
screening are conducted on cultured monolayer cells 
and, therefore, cannot reflect complex response to cyto-
toxic agents, targeted therapeutics (e.g., tyrosine kinase 
inhibitors, TKIs) and antibodies at tissue levels (Phung 
et al. 2011). This paper describes a novel approach to test 
in vitro toxicity in a microtissue setting, where microtis-
sues of a defined size and shape are formed by seeding 
equal counts of cells in hanging-drop plates. Cells culti-
vated on plastic surfaces expected to exhibit an increased 
sensitivity to cytotoxic drugs, while compounds targeting 
cell–cell adhesions, cell maturation, epithelial mesenchy-
mal transition (EMT) and stemness features often show a 
decreased efficacy in 3D cell culture (Amann et al. 2014). 
The in vivo-like microenvironment of in vitro microtis-
sues is the result of numerous factors including the for-
mation of molecular gradients within the microtissues 
(e.g., nutrients, oxygen, growth factors, as well as metab-
olites and paracrine factors) (Thoma et al. 2014; Achilli 
et al. 2012). In addition, microtissues develop an in vivo-
like microenvironment by forming more complex cell-to-
cell interactions and cell-to-ECM adhesions. These serve 
as additional signals, including mechanical forces and 
biochemical signals, that can influence cell shape, motil-
ity, proliferation, differentiation, as well as gene expres-
sion (Pampaloni et al. 2007; Achilli et al. 2012; Asthana 
and Kisaalita 2012; Lovitt et al. 2014). Thus, 3D cell cul-
ture models reflect in vivo tumour growth more reliably 
and can provide better read outs for drug testing (Amann 
et al. 2014).
To evaluate the effect of cytotoxic/cytostatic substances 
on this three-dimensional arrangement of cells, we inves-
tigated cells for their viability and proliferation. There are 
different methods available to verify cellular conditions 
of cells cultivated in a 2D setting. To investigate which 
of these assays are compatible to quantify proportions of 
viable, apoptotic, necrotic and proliferating cells in micro-
tissues, we adapted a panel of commercially functional 
assays for the advanced screening of cells in 3D micro-
tissues. The cell viability in a particular experiment can 
be illustrated by measuring: (1) adenosine triphosphate 
(ATP) levels (Crouch et al. 1993), (2) the integrity of cel-
lular membranes and (3) the activity of cellular enzymes, 
such as lactate dehydrogenase (LDH) (Chan et al. 2013). 
To test for the validity of assay results,(4) flow cytometry 
analyses using annexin V and propidium iodide were per-
formed. To differentiate between cytotoxic and cytostatic 
effects, we additionally performed (5) cell cycle analyses. 
The confirmation of all results was performed by light 
microscopy of microtissues. The focus of the outlined 
work is to test the compatibility of different assay sys-
tems to investigate viability and proliferation as well as 
the analysis and comparison of the differential response 
of the NSCLC cell line Colo699 cultivated in 2D and 3D 
to various anticancer therapeutics: Afatinib (BIBW 2992), 
as a representative of the current generation of TKIs, 
which irreversibly targets EGFR/HER2 (ErbB1/EGFRwt, 
EGFRL858R, EGFRL858R/T790M, ErbB2/HER2, and ErbB4), 
cisplatin, an inhibitor of DNA replication, and vinorelbine 
which prevents microtubuli polymerization, and, there-
fore, inhibits mitosis. We established a quantitative and 
qualitative method for the characterization of tumor cell 




Afatinib, cisplatin and vinorelbine (Selleckchem) were 
reconstituted in DMSO and stored as aliquots at −80 °C 
until use. Predilutions in DMSO and dilutions in medium 
were performed immediately before use. RNase A (Sigma) 
was reconstituted in A. dest. at a concentration of 10 mg/
ml, Propidium Iodide (Sigma) was dissolved in A. dest. at a 
concentration of 1 mg/ml.
Cell culture
The human non-small cell lung cancer cell line Colo699 
(DSMZ, ACC196) was used. For 2D culture, cells were 
cultivated as monolayer in DMEM low glucose (Lonza) 
supplemented with 10 % fetal calf serum (FCS) (Sigma-
Aldrich, Munich, Germany, Lot 010M3396) and 100 U/
ml penicillin, 100 mg/ml streptomycin solution, and 2 mM 
l-glutamine (PAA). Cells were cultivated at 37 °C in a 
humidified 5 % CO2-containing atmosphere. For cytotoxic-
ity studies, cells were either cultivated in 12-well plates at 
a density of 45,000 cells per well or in 96-well plates at a 
density of 5000 cells per well, respectively for 5 days.
Microtissue culture
For the production of 3D cultures, the Gravity-PLUS™ 
microtissue culture system (InSphero AG, Zurich, Switzer-
land) was used. The cultivation strategy was performed as 
described earlier (Amann et al. 2014) comprising the fol-
lowing modifications: after cells had been grown subconflu-
ently in cell culture plates (Falcon), they were seeded into 
the hanging-drop plates. Therefore, cells were washed once 
with PBS and detached with Accutase (PAA) for 5 min at 
37 °C. Thereafter, the enzymatic reaction was stopped with 
addition of cell culture medium. Then, cells were counted 
and seeded in 40 µl drops at a density of 2500 cells/drop. 
Cells were allowed to aggregate for 5 days.
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Cell and microtissue treatments
After 5 days of cultivation, half of the initial volume (20 µl 
from the microtissues; 50 µl of the 2D wells) was aspirated 
and fresh medium containing cisplatin (final concentration: 
800, 400, 200 and 100 µM), vinorelbine (final concentra-
tion: 200, 100, 50 and 25 µM), or afatinib (final concen-
tration: 80, 40, 20, and 10 µM) was added, respectively. 
Control microtissues and cells were treated with the cor-
responding amount of DMSO which was denoted as vehi-
cle in the outlined work. Assays were performed after 24 
and 48 h of treatment. Therefore, the cells and supernatants 
were inserted in the assays stated below.
Supernatant harvesting
The supernatants of four 3D microtissues (4 × 20 µl) 
and two 2D wells (2 × 75 µl) were pooled for each sub-
stance concentration to be inserted into the outlined assays 
(Table 1) mentioned below. The remaining medium per 
well of the 96-well plate was 25 µl and the remaining 
medium per capillary of the microtissue plate was 20 µl, 
respectively.
Assay type Volume/assay [µl]






Determination of ATP content (intra‑cellular)
The commercially available CellTiter-Glo® lumines-
cent cell viability assay kit (Promega) was used with the 
following modifications: To quantify intra-cellular ATP, 
25 µl CellTiter-Glo was added to the remaining cells in 
the 96-well plate and 20 µl CellTiter-Glo was added to the 
remaining microtissues in the capillaries. The cells and 
microtissues were then incubated at room temperature 
for 30 min. The detection of the luminescence signal was 
performed in a white microtiter plate using a VICTOR X5 
2030 Multilabel Reader (Perkin Elmer, MA, USA).
Determination of LDH release (extra‑cellular)
The commercially available CytoTox-ONE™ Homogene-
ous Membrane Integrity Assay (Promega) was performed 
with the following adaptations: to quantify LDH release 
20 µl substrate was added to 20 µl supernatant and incu-
bated for 10 min at room temperature. The enzymatic reac-
tion was stopped using 10 µl stop solution.
Determination of LDH retention (intra‑cellular)
Cell and microtissue cultivation, treatment and collection 
of supernatant of the cells and microtissues were performed 
as described in the above section. For quantification of the 
intra-cellular LDH content, the commercially available 
CytoTox-ONE™ Homogeneous Membrane Integrity Assay 
Table 1  Correlation of ATP 
and LDH assays with flow 
cytometry
Assay results of intra-cellular ATP and LDH release are correlated with data gained from cytometry analy-
sis-based viability data
* Correlation is significant at the 0.05 level (2-tailed)
** Correlation is significant at the 0.01 level (2-tailed)
Cultivation (duration) 24 h Treament
Afatinib Cisplatin Vinorelbine
ATP LDH ATP LDH ATP LDH
2D (5 days) 0.865 −0.782 0.966** −0.333 0.957* −0.933*
3D (5 days) 0.996** −0.993** 0.988** 0.729 0.939* −0.987**
3D (10 days) 0.996** −0.991** 0.971** −0.425 0.717 −0.770
Cultivation (duration) 48 h Treatment
Afatinib Cisplatin Vinorelbine
ATP LDH ATP LDH ATP LDH
2D (5 days) 0.877 −0.550 0.952* −0.655 0.879* −0.845
3D (5 days) 0.937* −0.929* 0.942* −0.865 0.961** −0.965**
3D (10 days) 0.985** −0.995** 0.943* −0.769 0.909* −0.919*
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(Promega) was performed with the following modifica-
tions: 20 and 25 µl lysis solution (cell culture medium/2 % 
Triton-X100) was added to 20 µl of the remaining superna-
tant of the microtissues and 25 µl of the remaining super-
natant of the cells, respectively. After addition of lysis 
solution, a final concentration of 1 % Triton-X100 was 
achieved. Complete lysis of cells and microtissues was 
achieved after an incubation of 5 h at 37 °C. The quantifi-
cation of the LDH content in the supernatant was depicted 
in the section above.
Apoptosis detection by annexin V/propidium iodide
At least four microtissues were pooled in one tube and 
washed with PBS twice. After complete buffer removal, 
microtissues were immersed in 300 µl Accumax (Mil-
lipore) and incubated for 30 min at 37 °C while vortex-
ing after 15 min. The cells cultivated in 12-well plates 
were detached using accutase (PAA, Pasching, Austria). 
The enzymatic reaction was stopped with 1 ml complete 
medium. The cells were centrifuged and washed with PBS. 
The cell pellet was then resuspended in 200 µl annexin 
binding buffer, including 2 µl annexin APC (BD, #550475) 
and 1 µl propidium iodide (50 µg/ml). For the analyses on a 
FACS Calibur (BD), at least 10,000 cells were captured and 
evaluated using FlowJo v10.
Cell cycle determination
Cell and microtissue harvesting and cell preparation was 
performed as in the apoptosis detection protocol. Cell cycle 
determination was adjusted from the original protocol from 
Riccardi and Nicoletti (2006). Therefore, cells were centri-
fuged and resuspended in 1 ml PBS. Fixation of cells was 
performed by addition of 2.5 ml ethanol while vortexing 
the cell suspension. Cells were incubated at −20 °C over-
night. Afterward, they were incubated with 250 µl staining 
buffer (0.05 % Triton X-100, 0.05 mg/ml propidium iodide, 
0.1 mg/ml RNaseA) for 40 min at 37 °C. After centrifuga-
tion and resuspension in with 300–500 µl PBS for cytom-
etry, analyses were performed on a FACS Calibur (BD) 
where at least 8000 cells were captured and evaluated using 
FlowJo v7.6.5.
Light microscopic assessment
Morphological appearances of the Colo699 microtissues 
and their structural changes after four, 24 and 48 h of treat-
ment by afatinib, cisplatin or vinorelbine were observed 
using an Olympus IX70 (Japan) inverted light microscope. 
The images were captured using the ProgRes CapturePro 
2.6 software (Jenoptic Germany) at a 400× magnification.
Statistical analysis
Data were analysed from three independent experiments 
performed in triplicates by normalizing to fluorescence 
or luminescence of wells and microtissues containing 
vehicle-treated cells. Statistical analyses were performed 
using SPSS Version 22. Global differences in assays 
were evaluated by an independent sample Kruskal–
Wallis test followed by pairwise comparison using the 
Mann–Whitney U test. A p value of ≤0.05 was taken 
as statistically significant. Graphs were prepared using 
GraphPad Prism Version 5.03. Results were expressed as 
mean ± standard error (SEM). The statistical relation-
ship between ATP, LDH assays and cytometry analyses 
was determined by a Kolmogorov–Smirnoff test to prove 
normal distribution followed by a Pearson correlation 
analysis.
Results
We generated Colo699 microtissues using the hanging-
drop technology; cells and microtissues were cultivated as 
follows: 2D for 5 days and 3D for 5 and 10 days. The out-
lined investigations confirm that assays based on tumor cell 
microtissues are suitable to indicate and quantify effects of 
compounds on tumour cell survival and proliferation. To 
characterize cellular cytotoxicity in greater detail, various 
assays were performed followed by a flow cytometry anal-
ysis to confirm assay results.
Assessment of viability by intra‑cellular ATP (lysate)
Afatinib treatment led to a dose-dependent reduction of 
intra-cellular ATP, an indicator of cell viability. Elevated 
levels of ATP and, thus, higher viabilities were observed 
in long-term cultivated microtissues. Statistical signifi-
cance compared to 2D cultivated cells was reached only 
at higher doses of Afatinib (40–80 µM) (Fig. 1). A dose-
dependent reduction of intra-cellular ATP in microtis-
sue and cell lysates induced by cisplatin treatment was 
observed. After 24 h of treatment significantly higher 
levels of ATP, indicating a better viability, were found in 
cisplatin-treated microtissues cultivated for 10 days com-
pared to cells cultivated in 2D. Two-dimensionally culti-
vated cells have significantly less intra-cellular ATP after 
48 h of treatment even compared to microtissues culti-
vated for 5 days (Fig. 2). Vinorelbine treatment induced a 
dose-dependent reduction of ATP in microtissue and cell 
lysates, which is even more pronounced after 48 h. No 
significant beneficial effect of extended microtissue culti-
vation could be verified (Fig. 3).
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Assessment of membrane integrity (LDH)
The membrane integrity was determined measuring LDH 
release. Afatinib treatment of microtissues and cells 
led to a general dose-dependent increase of LDH in the 
supernatant. Significantly elevated levels of LDH were 
observed in 2D cultivated cells compared to microtis-
sues (5 and 10 days) treated with afatinib at doses of 
10–20 µM. This effect was irrespective of their cultiva-
tion duration (Fig. 1). Dose-dependent differences in 
LDH release after cisplatin treatment could hardly be 
observed after 24 but after 48 h. Solely after treatment 
with 100 µM cisplatin for 48 h statistical significantly 
higher LDH release in 2D than in microtissues (Fig. 2). 
Cells and microtissues responded to increasing vinorel-
bine doses with increased LDH release. There was no 
















































































































































2D (5d) 3D (5d) 3D (10d)
Fig. 1  Dose–response curves of afatinib. Cells and microtissues are 
treated with increasing doses of the tyrosine kinase inhibitor afatinib 
for 24 and 48 h. Response of 2D cultivated cells and microtissues to 
afatinib was determined measuring intra-cellular ATP, LDH release, 
and cell viability (*p < 0.05; n = 3 for ATP assay; n = 3–7 for LDH 
assay; n = 3–4 for flow cytometry)
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difference in LDH release between cells cultivated in 2D 
compared to 3D after 24 h of vinorelbine treatment, sig-
nificantly elevated LDH release from 2D cultivated cells 
treated with 25–50 µM vinorelbine was observed after 
48 h (Fig. 3).
Flow cytometry analysis
Complete disaggregation of the cells without affecting their 
viability was crucial for the precise detection of apopto-
sis of Colo699 microtissues using flow cytometry. In this 















































































































































2D (5d) 3D (5d) 3D (10d)
Fig. 2  Dose–response curves of cisplatin. Cells and microtissues are 
treated with increasing doses of the DNA-intercalating molecule cis-
platin for 24 and 48 h. Response of 2D cultivated cells and microtis-
sues to cisplatin was determined measuring intra-cellular ATP, LDH 
release, and cell viability (*p < 0.05; n = 3 for ATP assay; n = 3–7 
for LDH assay; n = 3–4 for flow cytometry)
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assay, the microtissues were dissociated using an enzy-
matic reaction, and the viability of individual cells was pre-
served after dissociation. Staining with Annexin V-PE and 
PI solution allowed us to differentiate between apoptotic 
cells (annexin+/PI−); late apoptotic cells (annexin+/PI+); 
necrotic cells (annexin−/PI+) and viable cells (annexin−/
PI−). Data of viable cells were included in the follow-
ing analyses. Afatinib treatment led to a dose-dependent 
reduction of viable cells cultivated in 2D as well as within 
microtissues. Significantly less viable cells were observed 
in microtissues treated with 40 µM compared to cells cul-
tivated in 2D. In general, viability data revealed by flow 
cytometry lead to the assumption that cells cultivated in 
3D are more susceptible to the cytotoxic effect of afatinib 
(Fig. 1). Exposure of the microtissues and cells to increas-
ing concentrations of cisplatin resulted in reduced viability 










































































































































2D (5d) 3D (5d) 3D (10d)
Fig. 3  Dose–response curves of vinorelbine. Cells and microtis-
sues are treated with increasing doses of the anti-mitotic microtubuli 
inhibitor vinorelbine for 24 and 48 h. The response of 2D cultivated 
cells compared to microtissues was determined measuring intra-cel-
lular ATP, LDH release and cell viability (*p < 0.05; n = 3 for ATP 
assay; n = 3–7 for LDH assay; n = 3–4 for flow cytometry)
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of the cultures. In general, increased cell viability of cells 
within microtissues compared to cells cultivated in 2D 
was observed almost throughout the complete cisplatin 
dose range, while significance was only reached after 24 h 
treatment with 100–400 µM (Fig. 2). It seems that micro-
tissues were more resistant to vinorelbine treatment after 
long-term cultivation. Significantly elevated levels of viable 
cells were detected in microtissues which were treated with 
25–200 µM vinorelbine for 24 h and 50–100 µM for 48 h 
(Fig. 3).
Validation and test assay comparison
The differential levels of intra-cellular ATP were quantified 
in lysates of two-dimensional cultivated cells and microtis-
sues. The ATP levels represent the metabolic activity of the 
cells and, therefore, could be used as an indicator of viabil-
ity. As a consequence of cell membrane damage, LDH is 
released to the cell culture supernatant. The cytoplasmic 
enzyme LDH has been used as a marker of cell damage, 
because of its stability in cell culture medium and its easy 
measurement after leakage out of cells with a compromised 
membrane. LDH activity is quantified through lactate to 
pyruvate conversion coupled to a resazurin to resorufin 
reduction. The amount of the fluorescent product is pro-
portional to the amount of LDH present in the cell culture 
supernatant (Legrand et al. 1992). Flow cytometry repre-
sents a valid instrument to confirm analyses data gained 
from ATP and LDH assays. The comparison of these three 
data sets showed moderate-to-strong correlation (Table 1), 
except for data revealed from LDH release from cells and 
microtissues treated with cisplatin.
LDH retention test
To verify if LDH release is influenced by treatments and to 
disprove substance-dependent accumulation of LDH within 
microtissues, we performed lysis of the microtissues and 
cells with Triton X-100 at a final concentration of 1 % and 
quantified total LDH. Microtissues and cells treated with 
vinorelbine and afatinib released LDH nearly completely. 
Afatinib and vinorelbine treatment led to a dose-dependent 
increase of LDH in the supernatant simultaneously intra-
cellular LDH, released while cells are lysed, decreased. 
Especially, microtissues treated with cisplatin retain most 
of the cellular LDH within the cells. Here, the majority of 
the LDH content is within the lysate of cisplatin-treated 
cells and microtissues (Fig. 4).
Cell cycle mediated drug response
Since many of the targeted pathways are involved in mito-
sis (Shapiro and Harper 1999), cell cycle analyses were 
performed to visualize cytostatic effects of treated cells 
cultivated in 2D compared to 3D. To examine the poten-
tial antiproliferative activity of different established thera-
peutics and their differential effects on cells cultivated in 
2D and 3D, cell cycle progression was examined by flow 
cytometry of PI-stained cells. Cell cycle analyses were 
performed using cells treated with sub-lethal doses of the 
above-mentioned therapeutics (afatinib 10 µM; cisplatin 
200 µM; and vinorelbine 25 µM) (Supplementary Table 1). 
In microtissues, afatinib treatment led to increased pro-
portions of cells in the G1 phase compared to cells culti-
vated on plates, while in S- and G2/M phase decreased cell 
counts are detected. However, the observed differences 
were solely significant in the G2/M phase between 2D and 
3D (5 days) cultivated cells. Treatment with 200 µM cispl-
atin resulted in a significant decrease of cells in the S- and 
G2/M phase together with an increase of cells in the G1 
phase of cells in microtissues compared to 2D cultivation 
within the time frame of 24 h. However, reduction of the 
proportion of microtissue cells within the G2/M phase did 
not reach significance after 48 h treatment. Treatment with 
25 µM vinorelbine led to a significant accumulation of cells 
in the G1 phase in microtissues cultivated for 10 days com-
pared to 2D cultivated cells. This effect goes hand in hand 
with a decrease of cells in the S- and G2/M phase (Fig. 5; 
Supplementary Table 1).
Light microscopy
Microtissue growth and integrity can easily be visualized 
by phase-contrast imaging. We observed that microtissues 
cultivated for 10 days are bigger than those cultivated for 
5 days indicating that cells are still proliferating. Afatinib-
treated microtissues seem to gain susceptibility to treat-
ment after long-term cultivation, whereas cisplatin and 
vinorelbine treatment showed a more distinct cytotoxic 
effect in microtissues cultivated for 5 days compared to 
those cultivated for 10 days. Treatment with cisplatin or 
vinorelbine showed a dose- and time-dependent break up 
of microtissue structures. Surprisingly, microtissues treated 
with 800 µM cisplatin showed plain edges despite most of 
the cells are dead as other methods revealed (Supplemen-
tary Figure 1).
Discussion
As NSCLC is associated with high mortality rates and poor 
clinical performance, an improvement in drug-efficacy test-
ing is still highly warranted. The 2D cell culture models 
employed in preclinical studies frequently suggest that anti-
cancer drugs have a higher efficacy than is subsequently 
observed in vivo (Singh et al. 2015). To close this gap, we 
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Fig. 4  Determination of treat-
ment-dependent LDH retention: 
afatinib and vinorelbine treat-
ment led to a dose-dependent 
increase of LDH in the superna-
tant (solid line) simultaneously 
intra-cellular LDH, released 
while cells are lysed, decreased 
(dashed line). The LDH retain-
ing effect is observed in cells 
and microtissues treated with 
cisplatin
2D 3D
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established a more relevant in vitro system based on a 3D 
cell culture model of the lung. Based on this model, we 
assessed the effects of the cytotoxic drugs cisplatin and 
vinorelbine, as well as the tyrosine kinase inhibitor afatinib 
on Colo699 cells cultured either in 2D or in a 3D hanging-
drop system. The main focus of this project was to validate 
the use of various established cytotoxicity and viability 
assays for their use within the hanging-drop microtissues, 
and to highlight the differences in drug efficacy between 
the culture systems and the relevance of prolonged culture 
time.
Similar investigations in microtissues representing other 
tumor entities, such as osteosarcoma, colorectal, breast or 
head, and neck squamous carcinoma cell lines underline 
the importance of improved drug-efficacy testing and the 
feasibility of 3D drug testing (Singh et al. 2015; Drewitz 
et al. 2011; Rimann et al. 2014; Onion et al. 2016; Lovitt 
et al. 2015). In addition, other lung cancer models, such 
as matrix gels, have been stressed for drug-testing appli-
cations by others (Onion et al. 2016; Lama et al. 2013). 
Based on the results of these studies and our prior work 
(Amann et al. 2014), we addressed the reproducibility and 
comparability of results and, especially, assays generated 
in our 3D system, as most works focused on one read-out 
method. Therefore, we repeated our tests for several stand-
ard drugs, using various complementary cytotoxicity assays 
(LDH, ATP, Annexin V/PI, and microscopic volume/diam-
eter assessment, as well as cell cycle analyses) within each 
run. ATP and LDH quantification as well as Annexin V/























































































Fig. 5  Determination of cytostatic effect: cells and microtissues are 
treated with increasing doses of the tyrosine kinase inhibitor afatinib, 
the DNA-intercalating molecule cisplatin and the anti-mitotic micro-
tubuli inhibitor vinorelbine for 24 and 48 h. The cytostatic response 
of 2D cultivated cells compared to microtissues was determined using 
cell cycle analyses
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assessment. Measurement of intra-cellular ATP, as marker 
of metabolic activity and cell viability (Chiarugi 2005) and 
extra-cellular LDH, a marker for membrane integrity and 
thus measurement for damaged cells, are expected to show 
the exact opposite demeanor. For vinorelbine, a dose- and 
time-dependent response was found and a perfect correla-
tion with flow cytometry data achieved. Interestingly, with 
cisplatin, ATP and flow cytometry showed also a concen-
tration- and time-dependent curve and a high correlation, 
but with the LDH assay, an intra-cellular accumulation was 
observed not reflecting the viability of the cells. These find-
ings are in line with Kendig and Tarloff (2007) and sup-
port our chosen approach of multi-assay testing to avoid 
drug/substance induced artefacts. Our data suggest that 
within the validation process, determination of total intra- 
and extra-cellular ATP and LDH content is an essential 
step to demonstrate the influence of therapeutics on ATP 
and LDH release prior to assay performance. Thus, we 
summarize that for accurate drug testing, high throughput 
methods, such as ATP or LDH measurements, after initial 
validation by light microscopy or flow cytometry provide 
a robust tool for drug cytotoxicity testing in a 3D model. 
Our data confirm the importance to include different assays 
and validation steps in drug testing, as various drugs might 
affect the read-out of a certain test, thus leading to under- 
or over-interpretation.
In addition, prior to drug-efficacy testing, the mode of 
action of a substance needs to be considered, as depicted 
in the results for vinorelbine, where few cytotoxic effects 
were measured accompanied by significant increase in cell 
cycle arrest.
Afatinib, a targeted, cytostatic drug, showed diverse effi-
cacy in 3D versus 2D with a higher vulnerability of the 3D 
system. Besides, a partially lack of correlation with flow 
cytometric assays, especially in 2D were observed.
These data underline the need for innovative drug-test-
ing models and the value of flow cytometry and micro-
scopic assessment of microtissue growth in the context of 
primarily cytostatic, targeted agents. In addition, extended 
testing with the inclusion of pathway analyses, as shown in 
the work of Singh et al. (2015), might further improve drug 
development. Furthermore, patient-derived approaches 
confirm our results, thus highlighting the usage of these 
models already in early drug development (Onion et al. 
2016).
Besides feasibility and reproducibility, we addressed 
the question of the ideal time point for drug-efficacy test-
ing in 3D, based on the hypothesis that microtissues mature 
over time of 3D cultivation accompanied with changes in 
expression profiles and drug resistance (Lovitt et al. 2014). 
Therefore, we used the two cultivation times of 5 and 
10 days to be compared to 2D-cultures. Our results showed 
a significant difference between the different periods of 
cultivation. These findings support the use of extended cul-
ture times in drug-efficacy testing in 3D cell culture sys-
tems and our system proved superior to others, while long-
time cultivation in 2D is not easily achieved.
In summary, we proved the hanging-drop 3D culture of 
lung cancer cell lines to be an innovative and feasible tool 
for early drug testing, which might reflect the in vivo situ-
ation more appropriately than standard 2D culture systems. 
The extended cultivation and treatment times will add fur-
ther impact of the 3D system, in addition to the presence of 
microenvironmental factors, such as cell–cell interactions 
and oxygen gradient within the microtissue (Thoma et al. 
2014).
Conclusion
As anticancer drug discovery moves away from the tradi-
tional cytotoxic substances to novel, molecular-targeted 
cytostatic drugs, many emerging new anticancer therapeu-
tics would be considered inactive under the conventional 
screen. Therefore, it is essential to focus on the integra-
tion of  innovative drug-screening methods to evaluate 
the potency of molecular-targeted therapeutics (Choi et al. 
2014). Microtissues can reproduce characteristics of avas-
cular tumor nodules and micrometastases of large solid 
tumors, and better replicate the barrier to drug penetration 
which is presented by dense tumor tissues (Drewitz et al. 
2011; Ma et al. 2012), as well as the nutrient, oxygen and 
drug gradients (Edmondson et al. 2014). In vitro 3D tissue 
models are increasingly used to complement 2D cell culture 
and animal model studies, as an attempt to improve the pre-
dictive capabilities of preclinical drug safety and efficacy 
testing (Amann et al. 2015). The advantage of drug testing 
using microtissues in hanging-drops is that observation and 
incubation time can be extended to >5 days (Drewitz et al. 
2011; Rimann et al. 2014) compared to a two-dimensional 
setting and several other 3D culture techniques, where cells 
reach confluence or lack nutrients and start to die. The 
implementation of 3D cell culture represents a tool to test 
cellular responses and influences of anticancer drugs in an 
in vivo mimicking system (Asthana and Kisaalita 2012; 
Drewitz et al. 2011; Takagi et al. 2007). Nevertheless, our 
work underlines the importance to consider the mechanism 
of action of a new substance, as well as the usage of differ-
ent assays to validate findings and exclude artificial find-
ings. Furthermore, a sufficient cultivation time is needed to 
form mature spheroids for drug-testing applications.
In summary, we provide evidence that validated assays 
which are used to illustrate the constitution of cells in a 
two-dimensional setting can also be utilized for tumor 
microtissues, but have to be adjusted to the mechanism of 
action and validated with different methods before high 
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throughput approaches with single assays are run. Moreo-
ver, we demonstrate that cells in a three-dimensional con-
text respond in a different way as compared to cells culti-
vated on plates, thus bridging the gap between in vitro and 
in vivo findings.
Acknowledgments Open access funding provided by University of 
Innsbruck and Medical University of Innsbruck. This work was sup-
ported by the Competence Center ONCOTYROL.
Compliance with ethical standards 
Conflict of interest Jens Kelm: Chief Scientific Officer, Co-Founder 
& Member of the Management Team of InSpheroAG; All other 
authors: no conflict of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Achilli TM, Meyer J, Morgan JR (2012) Advances in the formation, 
use and understanding of multi-cellular spheroids. Expert Opin 
Biol Ther 12(10):1347–1360
Amann A, Zwierzina M, Gamerith G, Bitsche M, Huber JM, Vogel 
GF et al (2014) Development of an innovative 3D cell culture 
system to study tumour–stroma interactions in non-small cell 
lung cancer cells. PLoS One 9(3):e92511
Amann A, Gamerith G, Huber JM, Zwierzina M, Hilbe W, Zwierzina 
H (2015) Predicting drug sensitivity by 3D cell culture models. 
memo Mag Eur Med Oncol 8(1):77–80
Asthana A, Kisaalita WS (2012) Microtissue size and hypoxia in HTS 
with 3D cultures. Drug Discov Today 17(15–16):810–817
Chan FK, Moriwaki K, De Rosa MJ (2013) Detection of necrosis 
by release of lactate dehydrogenase activity. Methods Mol Biol 
979:65–70
Chiarugi A (2005) “Simple but not simpler”: toward a unified picture 
of energy requirements in cell death. FASEB J 19(13):1783–1788
Choi SY, Lin D, Gout PW, Collins CC, Xu Y, Wang Y (2014) Lessons 
from patient-derived xenografts for better in vitro modeling of 
human cancer. Adv Drug Deliv Rev 79–80:222–237
Crouch SP, Kozlowski R, Slater KJ, Fletcher J (1993) The use of ATP 
bioluminescence as a measure of cell proliferation and cytotoxic-
ity. J Immunol Methods 160(1):81–88
Drewitz M, Helbling M, Fried N, Bieri M, Moritz W, Lichtenberg J 
et al (2011) Towards automated production and drug sensitivity 
testing using scaffold-free spherical tumor microtissues. Bio-
technol J 6(12):1488–1496
Edmondson R, Broglie JJ, Adcock AF, Yang L (2014) Three-dimen-
sional cell culture systems and their applications in drug dis-
covery and cell-based biosensors. Assay Drug Dev Technol 
12(4):207–218
Kendig DM, Tarloff JB (2007) Inactivation of lactate dehydrogenase 
by several chemicals: implications for in vitro toxicology stud-
ies. Toxicol In Vitro 21(1):125–132
Lama R, Zhang L, Naim JM, Williams J, Zhou A, Su B (2013) Devel-
opment, validation and pilot screening of an in vitro multi-cellu-
lar three-dimensional cancer spheroid assay for anti-cancer drug 
testing. Bioorg Med Chem 21(4):922–931
Legrand C, Bour JM, Jacob C, Capiaumont J, Martial A, Marc A et al 
(1992) Lactate dehydrogenase (LDH) activity of the cultured 
eukaryotic cells as marker of the number of dead cells in the 
medium [corrected]. J Biotechnol 25(3):231–243
Lovitt CJ, Shelper TB, Avery VM (2014) Advanced cell culture tech-
niques for cancer drug discovery. Biology 3(2):345–367
Lovitt CJ, Shelper TB, Avery VM (2015) Evaluation of chemothera-
peutics in a three-dimensional breast cancer model. J Cancer Res 
Clin Oncol 141(5):951–959
Ma HL, Jiang Q, Han S, Wu Y, Cui Tomshine J, Wang D et al (2012) 
Multicellular tumor spheroids as an in vivo-like tumor model for 
three-dimensional imaging of chemotherapeutic and nano mate-
rial cellular penetration. Mol Imaging 11(6):487–498
Onion D, Argent RH, Reece-Smith AM, Craze ML, Pineda RG, 
Clarke PA et al (2016) 3-Dimensional patient-derived lung can-
cer assays reveal resistance to standards-of-care promoted by 
stromal cells but sensitivity to histone deacetylase inhibitors. 
Mol Cancer Ther 15(4):753–763
Pampaloni F, Reynaud EG, Stelzer EH (2007) The third dimension 
bridges the gap between cell culture and live tissue. Nat Rev Mol 
Cell Biol 8(10):839–845
Phung YT, Barbone D, Broaddus VC, Ho M (2011) Rapid generation 
of in vitro multicellular spheroids for the study of monoclonal 
antibody therapy. J Cancer 2:507–514
Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium 
iodide staining and flow cytometry. Nat Protoc 1(3):1458–1461
Rimann M, Laternser S, Gvozdenovic A, Muff R, Fuchs B, Kelm JM 
et al (2014) An in vitro osteosarcoma 3D microtissue model for 
drug development. J Biotechnol 189:129–135
Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and 
checkpoint control. J Clin Invest 104(12):1645–1653
Singh M, Close DA, Mukundan S, Johnston PA, Sant S (2015) Pro-
duction of uniform 3D microtumors in hydrogel microwell 
arrays for measurement of viability, morphology, and signaling 
pathway activation. Assay Drug Dev Technol 13(9):570–583
Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug 
screening: empirical to target-driven approaches. Clin Cancer 
Res 11(3):971–981
Takagi A, Watanabe M, Ishii Y, Morita J, Hirokawa Y, Matsuzaki T 
et al (2007) Three-dimensional cellular spheroid formation pro-
vides human prostate tumor cells with tissue-like features. Anti-
cancer Res 27(1A):45–53
Thoma CR, Zimmermann M, Agarkova I, Kelm JM, Krek W (2014) 
3D cell culture systems modeling tumor growth determinants in 
cancer target discovery. Adv Drug Deliv Rev 69–70:29–41
